Regulated Bitcoin futures, launched in December 2017, marked a key milestone by allowing institutional investors to trade on both rising and falling prices, thus increasing market maturity and participation. Former CFTC chairman Christopher Giancarlo highlighted how futures enabled short selling, attracting professional investors and anchoring Bitcoin pricing in dollars. Despite growth, he warned of ongoing fraud risks requiring strong regulation and oversight. Digital assets are evolving into a foundational part of finance, reshaping banking and financial services globally.
Bitcoin futures and their institutional impact provide context for cryptocurrency market activity on Pluang as of Nov 02, 2026 20:43 WIB: out of 50 major cryptocurrencies, 8 rose and 41 fell. Notable movers include EGLD at Rp60.408 with a 1-day change of -3.62% and a typical hold time of 86 days, ONE at Rp20 with a -3.24% change and 154 days hold time, and ENJ at Rp430 with a -3.08% change and 106 days hold time. Pluang order activity shows EGLD heavily sold at 95% sell versus 5% buy, ONE more balanced at 42% sell and 58% buy, and ENJ predominantly sold at 98% sell versus 2% buy.
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
